Gilead Sciences Chief Scientific Officer John McHutchison to Leave

By Colin Kellaher

Gilead Sciences Inc. (GILD) on Wednesday said three executives, including its top researcher, will be leaving the biopharmaceutical company.

Gilead said John McHutchison is stepping down as chief scientific officer and head of research and development, effective Aug. 2.

The Foster City, Calif., company said it will immediately commence a search for his successor.

Mr. McHutchison, who joined Gilead in 2010 and has been chief scientific officer since March 2018, will receive a lump-sum payment of $1.1 million as part of a transition agreement, the company said.

Separately, Gilead said Chief Patient Officer Gregg Alton and Katie Watson, executive vice president of human resources, will also be leaving the company.

Mr. Alton, who joined Gilead in 1999, will remain through Oct. 4 and will serve as an adviser until the end of the year to help transition his duties to other parts of the company.

Gilead said Jyoti Mehra, who joined the company in 2017 as vice president of human resources, will succeed Ms. Watson as executive vice president of human resources, effective Aug. 5.

Ms. Watson, who joined Gilead in 2003, will leave on Sept. 1 but will advise on the transition through the end of the year, Gilead said.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 17, 2019 09:09 ET (13:09 GMT)

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024